Djavad Mowafaghian Centre for Brain Health and Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.
University of California, San Francisco, San Francisco, CA, USA.
Mult Scler. 2018 Jan;24(1):64-68. doi: 10.1177/1352458517737369.
Half of our cells and only 1 in 100 of our genes are human; the rest comprise microbes, termed the human microbiota. Over 90% of these microbes live in the large intestine. Aside from aiding food digestion, these diverse microbes can also synthesize essential vitamins or amino acids, educate and modulate the immune system response, and influence susceptibility or resistance to infections. Their potential to influence neurological conditions such as multiple sclerosis (MS) is intriguing. The overarching goal of this Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) presentation was to provide a high-level insight into gut microbiota's potential role in pediatric MS. Two specific questions were also addressed based on published work: (1) Does the gut microbiota differ between children with and without MS? and (2) Is the gut microbiota associated with future relapse risk?
我们的细胞有一半，而基因只有 1/100 是人类的；其余的由微生物组成，称为人类微生物组。这些微生物中超过 90% 存在于大肠中。除了帮助消化食物外，这些多样化的微生物还可以合成必需的维生素或氨基酸，教育和调节免疫系统反应，并影响对感染的易感性或抵抗力。它们对多发性硬化症 (MS) 等神经疾病产生影响的潜力令人着迷。本次美国多发性硬化治疗和研究委员会 (ACTRIMS) 报告的总体目标是提供对肠道微生物组在儿科多发性硬化症中的潜在作用的高级见解。根据已发表的研究，还提出了两个具体问题：（1）患有和不患有 MS 的儿童的肠道微生物组是否存在差异？（2）肠道微生物组是否与未来的复发风险相关？
